Institutional members access full text with Ovid®

Smoking Cessation in a Community Alcohol and Drug Service: Acceptability and Feasibility

Deal, Heather MPH; Newcombe, David A. L. PhD; Walker, Natalie PhD; Galea, Susanna MD

Addictive Disorders & Their Treatment: December 2014 - Volume 13 - Issue 4 - p 199–209
doi: 10.1097/ADT.0000000000000037
Original Articles

Objectives: This study was undertaken to determine if delivering smoking cessation (SC) treatment within a Community Alcohol and Drug Service (CADS) is feasible and/or effective.

Materials and Methods: Clinicians (n=16) from a single CADS received SC training, then implemented that training with clients who smoked tobacco. Participating clients (n=16) received a box containing 5 different nicotine replacement therapies (NRT) to try out in any combination over 1 week. Clients were then encouraged to choose 1 or 2 NRT products to use for an additional 4 weeks. Data collection from both clinicians and CADS clients occurred at baseline, 1 week, 2 to 4 weeks, and 5 weeks.

Results: Clinicians: Many clinicians regarded the training positively and felt confident in providing SC treatment to their clients. At the end of the study, 88% felt that SC treatment should become part of routine clinical practice. Clients: At 5 weeks, 2 clients had achieved verified continuous abstinence, and 6 clients (50%) had reduced the number of cigarettes smoked per day. Most clients preferred to use combination NRT therapy.

Conclusions: Providing SC support to smokers within a substance abuse treatment service in New Zealand is feasible and effective in motivating clients to make a quit attempt or at least reduce their cigarette consumption.

*Social and Community Health

National Institute for Health Innovation, School of Population Health, Faculty of Medical and Health Sciences, University of Auckland

Community Alcohol and Drug Services, Waitemata District Health Board, Auckland, New Zealand

The present study was funded by the New Zealand Ministry of Health. Natalie Walker (NW) has provided consultancy to the manufacturers of smoking cessation medications, received honoraria for speaking at a research meeting and received benefits in kind and travel support from a manufacturer of smoking cessation medications. She has also undertaken two trials of very low nicotine content cigarettes, which were purchased from two different tobacco companies. For the remaining authors no conflicts of interest were declared.

Reprints: David A. L. Newcombe, PhD, Social and Community Health, School of Population Health, University of Auckland-Tamaki Campus, Private Bag 92019, Auckland 1142, New Zealand (e-mail: d.newcombe@auckland.ac.nz).

Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved